Welcome to our dedicated page for Syros Pharmaceut news (Ticker: SYRS), a resource for investors and traders seeking the latest updates and insights on Syros Pharmaceut stock.
Syros Pharmaceuticals (SYRS) is a leader in gene regulation research, developing novel therapies for oncology and hematologic malignancies through its integrated platform of assay technologies and bioinformatics. This page provides centralized access to all official company announcements, press releases, and third-party analyses related to SYRS's scientific advancements and corporate developments.
Investors and researchers will find timely updates on clinical trial progress, regulatory milestones, and strategic partnerships. Our curated collection includes updates on SYRS's drug discovery pipeline, financial results, and peer-reviewed research collaborations – all organized for efficient tracking of the company's progress in transforming gene control insights into therapeutic solutions.
Key content categories include clinical trial announcements, FDA regulatory updates, partnership disclosures with academic institutions, quarterly earnings reports, and scientific conference presentations. Each entry is verified for accuracy and relevance to SYRS's core mission of advancing precision medicine through gene regulatory circuit mapping.
Bookmark this page for streamlined monitoring of SYRS's developments in hematologic and oncology research. Check back regularly for authoritative updates on how Syros Pharmaceuticals continues to pioneer new approaches in targeted drug discovery.
Syros Pharmaceuticals (NASDAQ: SYRS) announced a grant of 31,000 restricted stock units (RSUs) to a newly hired employee as an inducement for employment. This grant aligns with Nasdaq rule 5635(c)(4) and was awarded on July 29, 2022. The RSUs vest in four increments, with the first quarter vesting on March 31, 2023, and subsequent quarters annually, contingent on continued employment. Syros is focused on developing gene expression control medicines, with a pipeline that includes treatments for acute myeloid leukemia and solid tumors.
Syros Pharmaceuticals (NASDAQ:SYRS) announced that the European Medicines Agency (EMA) has issued a positive opinion for orphan drug designation for tamibarotene, aimed at treating myelodysplastic syndrome (MDS). This designation follows the FDA's granting of the same status in February 2022. Tamibarotene is currently being evaluated in the SELECT-MDS-1 Phase 3 trial alongside azacitidine for higher-risk MDS patients. Results from this trial are due in late 2023 or early 2024, with a potential new drug application filing anticipated next year.
Syros Pharmaceuticals (NASDAQ:SYRS) announced a live conference call and webcast on August 9, 2022, at 8:30 a.m. ET to discuss its second quarter 2022 financial results and provide a corporate update. Investors can access the call by dialing (833) 636-1323 domestically or (412) 902-4279 internationally, or via its website. Syros is focused on developing innovative medicines that control gene expression, with a robust pipeline including tamibarotene for myelodysplastic syndrome and acute myeloid leukemia, among other candidates.
Syros Pharmaceuticals announced a merger agreement to acquire TYME Technologies, gaining approximately
Syros Pharmaceuticals (NASDAQ: SYRS) announced the grant of restricted stock units (RSUs) for 48,400 shares to two new employees as an employment inducement per Nasdaq Listing Rule 5635(c)(4). The RSUs vest annually over four years, contingent on continued service. Syros is focused on gene expression control, advancing a clinical pipeline that includes tamibarotene for myelodysplastic syndrome, SY-2101 for acute promyelocytic leukemia, and SY-5609 for select solid tumors.
Syros Pharmaceuticals (NASDAQ:SYRS) announced that CEO Nancy Simonian will participate in a fireside chat at the JMP Securities Life Sciences Conference on June 15 at 9:30 a.m. ET, held at The Lotte New York Palace, NY. Attendees can join via a live webcast on Syros's website, with an archived replay available for 30 days. Syros focuses on developing medicines that control gene expression for diseases like myelodysplastic syndrome and leukemia, with a clinical pipeline that includes innovative treatments such as tamibarotene and SY-2101.
Syros Pharmaceuticals (NASDAQ: SYRS) has granted an aggregate of 77,850 restricted stock units (RSUs) to four new employees, effective May 31, 2022. These RSUs serve as material inducements in accordance with Nasdaq Listing Rule 5635(c)(4) and will vest over four years, subject to the employees’ continued service. Syros aims to leverage its gene control technology in advancing treatments for certain cancers, with a clinical pipeline that includes innovative therapies like tamibarotene and SY-5609.
Syros Pharmaceuticals (SYRS) reported Q1 2022 revenues of $5.5 million, up from $4.8 million in Q1 2021. The company reported a net loss of $25.1 million or $0.40 per share, compared to a loss of $14.2 million or $0.23 per share in the prior year. Key developments include ongoing trials: SELECT-MDS-1 with expected data in Q4 2023/Q1 2024, and SELECT-AML-1 Phase 2 due in the second half of 2022. The company deprioritized SY-5609 in hematologic malignancies due to current market conditions and plans to secure additional capital before advancing SY-2101 into Phase 3.
Syros Pharmaceuticals (SYRS) announced a live conference call and webcast for May 16, 2022, at 8:30 a.m. ET to discuss its Q1 2022 financial results and provide corporate updates. Investors can access the call via telephone (866-595-4538 domestic) or through the company's website. Syros focuses on developing small molecule medicines that manipulate gene expression and has a pipeline featuring tamibarotene for myelodysplastic syndrome and leukemia, SY-2101 for acute promyelocytic leukemia, and SY-5609 for solid tumors and blood cancers.
Syros Pharmaceuticals (NASDAQ: SYRS) has granted 136,750 restricted stock units (RSUs) to six new employees as part of their employment agreement, complying with Nasdaq Listing Rule 5635(c)(4). These awards will vest quarterly, starting April 30, 2023, contingent on continued employment. Syros is focused on developing innovative gene expression medicines, with a pipeline that includes tamibarotene for myelodysplastic syndrome and acute myeloid leukemia, SY-2101 for acute promyelocytic leukemia, and SY-5609 for solid tumors and blood cancers.
FAQ
What is the current stock price of Syros Pharmaceut (SYRS)?
What is the market cap of Syros Pharmaceut (SYRS)?
